Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI318 in Advanced Cutaneous Squamous Cell Carcinoma
CTR20202143Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Oct 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of reozalimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Innovent Biologics. Started Oct 2020; status: terminated.
02
Drugs
reozalimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on CTR20202143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202143.